Vincent Vultaggio - 06 Feb 2026 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Signature
/s/ James B. Bucher, attorney-in-fact for Vincent Vultaggio
Issuer symbol
ZNTL
Transactions as of
06 Feb 2026
Net transactions value
-$97,557
Form type
4
Filing time
10 Feb 2026, 21:10:25 UTC
Previous filing
04 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vultaggio Vincent PAO and PFO C/O ZENTALIS PHARMACEUTICALS, INC., 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO /s/ James B. Bucher, attorney-in-fact for Vincent Vultaggio 10 Feb 2026 0002018766

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale $72,772 -29,951 -16% $2.43 156,779 06 Feb 2026 Direct F1
transaction ZNTL Common Stock Sale $8,086 -3,379 -2.2% $2.39 153,400 09 Feb 2026 Direct F1
transaction ZNTL Common Stock Sale $16,699 -6,894 -4.5% $2.42 146,506 10 Feb 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2025.